Medtronic PLC (NYSE:MDT) Stock Has Consensus Price Target of $102.92 According to Brokerages

Shares of Medtronic PLC (NYSE:MDT) have received a consensus rating of “Moderate Buy” from the twenty-eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and seventeen have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $102.88.

A number of analysts have recently issued reports on the stock. Truist Financial reaffirmed a “hold” rating and set a $99.00 price objective (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $92.00 price target on shares of Medtronic in a research report on Thursday, September 3rd. Bank of America increased their price objective on Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Barclays raised Medtronic to a “hold” rating in a report on Wednesday, October 7th. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Wednesday.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026
• Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up?
• Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group
• Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler
• Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

Medtronic Price Performance

Shares of NYSE:MDT traded down $0.66 on Friday, hitting $94.79. The company’s stock had a trading volume of 30,274,266 shares, compared to its average volume of 33,123,818. Medtronic has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The company has a market capitalization of $121.25 billion, a PE ratio of 23.35, a PEG ratio of 2.17 and a beta of 0.55. The company has a 50-day simple moving average of $91.03 and a 200 day simple moving average of $85.01.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Sell-side analysts forecast that Medtronic will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were paid a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Insider Transactions at Medtronic

In other news, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares in the company, valued at approximately $10,167,936. The trade was a 8.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the sale, the chief executive officer directly owned 277,866 shares of the company’s stock, valued at $26,397,270. This trade represents a 15.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MDT. Kintegral Advisory LLC lifted its position in Medtronic by 0.6% in the third quarter. Kintegral Advisory LLC now owns 49,276 shares of the medical technology company’s stock valued at $4,288,000 after purchasing an additional 278 shares during the last quarter. Avail Investment Partners LLC bought a new position in shares of Medtronic in the third quarter worth approximately $291,000. Hengehold Capital Management LLC increased its stake in shares of Medtronic by 1.7% in the third quarter. Hengehold Capital Management LLC now owns 42,768 shares of the medical technology company’s stock worth $3,690,000 after buying an additional 733 shares during the period. Cardinal Capital Management Inc. increased its stake in shares of Medtronic by 3.4% in the third quarter. Cardinal Capital Management Inc. now owns 340,500 shares of the medical technology company’s stock worth $29,382,000 after buying an additional 11,325 shares during the period. Finally, Cyndeo Wealth Partners LLC raised its holdings in Medtronic by 4.6% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 7,680 shares of the medical technology company’s stock valued at $663,000 after buying an additional 339 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.